SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD — Hubert H. Humphrey Synthetic CCD

PatientHubert H. Humphrey
Date of birth1960-05-27
IdentifiersMRN HR-ML022-SYN; SSN (made up) 000-22-8047
Document date2026-11-01
AuthorWalter Brandvold, MD
CustodianSt. Posthumous Health Center

Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.

Reason for Visit

First visit to establish shared care three months after radical cystoprostatectomy with an ileal conduit for bladder cancer. Concerns: Wants his follow-up after bladder removal and his urostomy managed close to home and work; Bothered by appliance leaks and sore skin around the stoma, which interrupt his long working days. [S]

Allergies and Intolerances

AllergyReactionStatusEvidence
No known allergyactiveS

Medications

MedicationFrequencyRouteDatesStatusEvidence
Sodium bicarbonate 650 mg oral tablet, one tablet by mouth twice daily, for metabolic acidosis after an ileal conduitOne tablet twice dailyOral route2026-04-07activeS
Ciprofloxacin 500 mg oral tablet, one tablet by mouth twice daily for 7 days, for acute pyelonephritisOne tablet twice daily for 7 daysOral route2026-03-17 to 2026-03-23completedS

Procedures

ProcedureDatesStatusEvidence
Cystoscopy and transurethral resection of bladder tumors, at the cancer center: recurrent multifocal papillary urothelial carcinoma, low grade, with high-grade carcinoma in situ in random biopsies; muscularis propria present and not invaded (cTa with CIS); small, poorly compliant bladder after earlier radiation2025-09-02 to 2025-09-02completedS
Staging CT of the chest, abdomen, and pelvis with CT urography: thickened bladder wall; no hydronephrosis, upper-tract filling defect, enlarged lymph nodes, or distant disease2025-09-16 to 2025-09-16completedS
Radical cystoprostatectomy with bilateral pelvic lymph node dissection, partial urethrectomy, and ileal conduit urinary diversion, stoma in the right lower abdomen, at the cancer center. Pathology: multifocal urothelial carcinoma, high grade, with carcinoma in situ, invading the inner half of the muscularis propria (pT2a); 0 of 18 lymph nodes (pN0); ureteric and urethral margins negative; prostate with benign hyperplasia and no urothelial involvement2025-10-07 to 2025-10-07completedS
Renal ultrasound at six months: no hydronephrosis on either side; normal kidney size and cortical thickness; conduit decompressed2026-04-07 to 2026-04-07completedS
Advance care planning conversation, about 20 minutes2026-06-02 to 2026-06-02completedS

Immunizations

DateVaccineStatusEvidence
2025-11-18High-dose influenza vaccine, this seasoncompletedS
2020-03-10Tdap vaccinecompletedS
2026-06-02Pneumococcal conjugate vaccine PCV20completedS
2026-06-02Recombinant zoster vaccine, dose 1 of 2completedS

Past Medical History

Historical biography with true dates. These events are not part of the synthetic care timeline.

Historical dateHistoryEvidence
1967Blood in the urine; bladder cancer suspected by some physicians but not treatedD (CLM-0003)
1968Several small benign bladder growths found and removedD (CLM-0003)
1973Possibly cancerous bladder tissue treated with thiotepa and X-ray therapy, five minutes a day for five weeksD (CLM-0004)
October 1976Radical cystectomy with removal of the prostate, lymph nodes, and part of the urethra, and a urinary conduit made from small intestine, after a low-grade malignancy was found on examination for urinary infection symptomsD (CLM-0005)

Family History

No family medical history is documented in the logged sources. Family history of real relatives is recorded only from documented or retrospective sources and is never synthesized.

Health Concerns

ConcernStatusEvidence
Wants his follow-up after bladder removal and his urostomy managed close to home and workactiveS
Bothered by appliance leaks and sore skin around the stoma, which interrupt his long working dayscurrentS

Assessment

Most recent measures: Sodium [Moles/volume] in Serum or Plasma 137 on 2026-03-17; Potassium [Moles/volume] in Serum or Plasma 4.6 on 2026-03-17; Chloride [Moles/volume] in Serum or Plasma 107 on 2026-03-17; Carbon dioxide, total [Moles/volume] in Serum or Plasma 20 on 2026-03-17; Urea nitrogen [Mass/volume] in Serum or Plasma 26 on 2026-03-17; Creatinine [Mass/volume] in Serum or Plasma 1.41 on 2026-03-17; Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M 55 on 2026-03-17; Calcium [Mass/volume] in Serum or Plasma 9.2 on 2026-01-06; Albumin [Mass/volume] in Serum or Plasma 3.7 on 2026-01-06; Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma 88 on 2026-01-06; Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma 22 on 2026-01-06; Hemoglobin [Mass/volume] in Blood 13.4 on 2026-04-07; Leukocytes [#/volume] in Blood by Automated count 12.6 on 2026-03-17; Platelets [#/volume] in Blood by Automated count 284 on 2026-01-06; Cobalamin (Vitamin B12) [Mass/volume] in Serum or Plasma 412 on 2026-01-06; Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] 3 on 2026-01-06; Patient Health Questionnaire 2 item (PHQ-2) total score [Reported] 0 on 2026-06-02; Leukocytes [#/area] in Urine sediment by Microscopy high power field 55 on 2026-03-17; Colony count [#/volume] in Urine 100000 on 2026-03-17; Total score [Mini-Cog] 5 on 2026-06-02; Total score [AUDIT-C] 2 on 2026-06-02; Cholesterol [Mass/volume] in Serum or Plasma 196 on 2026-06-02; Cholesterol in HDL [Mass/volume] in Serum or Plasma 46 on 2026-06-02; Cholesterol in LDL [Mass/volume] in Serum or Plasma by calculation 124 on 2026-06-02; Triglyceride [Mass/volume] in Serum or Plasma 130 on 2026-06-02 [S]

Strengths and supports: Supports: family, close friends, and a large circle of colleagues [S]

Problems

ProblemClinical statusVerificationCodeProvenance
Urothelial carcinoma of the bladder, multifocal, with carcinoma in situ, pT2a pN0 (0 of 18 nodes), margins negative, treated by radical cystoprostatectomy with an ileal conduit; no evidence of disease; under surveillance; synthetic modern detail linked to his documented bladder canceractiveconfirmed Z85.51S — Synthetic grade, stage, node count, and margins; the bladder growths, the earlier thiotepa and X-ray therapy, the low-grade malignancy, and the radical cystectomy with a small-intestine conduit are documented (D). Z85.51 is used because the tumor has been removed and no further treatment is directed at it.
Ileal conduit urostomy, right lower abdomenactiveconfirmed Z93.6S — The small-intestine conduit and the stoma to the right of the navel are documented (D); the coding and the stoma findings are synthetic.
Acquired absence of the bladder and part of the urethra after radical cystectomyactiveconfirmed Z90.6S — Documented operation (D); synthetic coding.
Acquired absence of the prostate after cystoprostatectomyactiveconfirmed Z90.79S — Documented operation (D); synthetic coding.
Personal history of pelvic radiation for bladder tumor, with earlier intravesical thiotepaactiveconfirmed Z92.3S — The thiotepa and X-ray therapy are documented (D); the coding and their relevance to the modern episode are synthetic.
Hyperchloremic metabolic acidosis from the ileal conduit, mildactiveconfirmed E87.22S — Synthetic finding at the six-month visit, a known effect of urine contact with the ileal segment.
Acute right pyelonephritis with an ileal conduit (Escherichia coli), with mild acute kidney injury, treated with oral ciprofloxacin and resolvedresolvedconfirmed N10S — Synthetic intercurrent infection at an unscheduled visit, a common complication of an ileal conduit; it does not echo a documented illness of his after the operation.

Results

DateMeasureValueUnitReference rangeFlagProvenance
2026-01-06Sodium [Moles/volume] in Serum or Plasma139mmol/L135-145 mmol/LNormalS
2026-01-06Potassium [Moles/volume] in Serum or Plasma4.3mmol/L3.5-5.1 mmol/LNormalS
2026-01-06Chloride [Moles/volume] in Serum or Plasma106mmol/L98-107 mmol/LNormalS
2026-01-06Carbon dioxide, total [Moles/volume] in Serum or Plasma22mmol/L22-29 mmol/LNormalS
2026-01-06Urea nitrogen [Mass/volume] in Serum or Plasma18mg/dL8-23 mg/dLNormalS
2026-01-06Creatinine [Mass/volume] in Serum or Plasma1.12mg/dL0.74-1.35 mg/dLNormalS
2026-01-06Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M73mL/min/{1.73_m2}>=60 mL/min/1.73 m²NormalS
2026-01-06Calcium [Mass/volume] in Serum or Plasma9.2mg/dL8.6-10.3 mg/dLNormalS
2026-01-06Albumin [Mass/volume] in Serum or Plasma3.7g/dL3.5-5 g/dLNormalS
2026-01-06Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma88U/L40-129 U/LNormalS
2026-01-06Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma22U/L7-55 U/LNormalS
2026-01-06Hemoglobin [Mass/volume] in Blood12.6g/dL13.2-16.6 g/dLLowS
2026-01-06Leukocytes [#/volume] in Blood by Automated count6.410*3/uL4-11 10*3/uLNormalS
2026-01-06Platelets [#/volume] in Blood by Automated count28410*3/uL150-400 10*3/uLNormalS
2026-01-06Cobalamin (Vitamin B12) [Mass/volume] in Serum or Plasma412pg/mL232-1245 pg/mLNormalS
2026-01-06Patient Health Questionnaire 9 item (PHQ-9) total score [Reported]3{score}S
2026-02-03Patient Health Questionnaire 2 item (PHQ-2) total score [Reported]0{score}S
2026-04-07Sodium [Moles/volume] in Serum or Plasma140mmol/L135-145 mmol/LNormalS
2026-04-07Potassium [Moles/volume] in Serum or Plasma4.2mmol/L3.5-5.1 mmol/LNormalS
2026-04-07Chloride [Moles/volume] in Serum or Plasma110mmol/L98-107 mmol/LHighS
2026-04-07Carbon dioxide, total [Moles/volume] in Serum or Plasma20mmol/L22-29 mmol/LLowS
2026-04-07Urea nitrogen [Mass/volume] in Serum or Plasma16mg/dL8-23 mg/dLNormalS
2026-04-07Creatinine [Mass/volume] in Serum or Plasma1.15mg/dL0.74-1.35 mg/dLNormalS
2026-04-07Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M71mL/min/{1.73_m2}>=60 mL/min/1.73 m²NormalS
2026-04-07Hemoglobin [Mass/volume] in Blood13.4g/dL13.2-16.6 g/dLNormalS
2026-04-07Patient Health Questionnaire 2 item (PHQ-2) total score [Reported]1{score}S
2026-07-07Sodium [Moles/volume] in Serum or Plasma140mmol/L135-145 mmol/LNormalS
2026-07-07Potassium [Moles/volume] in Serum or Plasma4.4mmol/L3.5-5.1 mmol/LNormalS
2026-07-07Chloride [Moles/volume] in Serum or Plasma106mmol/L98-107 mmol/LNormalS
2026-07-07Carbon dioxide, total [Moles/volume] in Serum or Plasma24mmol/L22-29 mmol/LNormalS
2026-07-07Urea nitrogen [Mass/volume] in Serum or Plasma17mg/dL8-23 mg/dLNormalS
2026-07-07Creatinine [Mass/volume] in Serum or Plasma1.1mg/dL0.74-1.35 mg/dLNormalS
2026-07-07Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M74mL/min/{1.73_m2}>=60 mL/min/1.73 m²NormalS
2026-07-07Patient Health Questionnaire 2 item (PHQ-2) total score [Reported]0{score}S
2026-03-17Leukocytes [#/volume] in Blood by Automated count12.610*3/uL4-11 10*3/uLHighS
2026-03-17Sodium [Moles/volume] in Serum or Plasma137mmol/L135-145 mmol/LNormalS
2026-03-17Potassium [Moles/volume] in Serum or Plasma4.6mmol/L3.5-5.1 mmol/LNormalS
2026-03-17Chloride [Moles/volume] in Serum or Plasma107mmol/L98-107 mmol/LNormalS
2026-03-17Carbon dioxide, total [Moles/volume] in Serum or Plasma20mmol/L22-29 mmol/LLowS
2026-03-17Urea nitrogen [Mass/volume] in Serum or Plasma26mg/dL8-23 mg/dLHighS
2026-03-17Creatinine [Mass/volume] in Serum or Plasma1.41mg/dL0.74-1.35 mg/dLHighS
2026-03-17Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M55mL/min/{1.73_m2}>=60 mL/min/1.73 m²LowS
2026-03-17Leukocytes [#/area] in Urine sediment by Microscopy high power field55/[HPF]<=5 /[HPF]HighS
2026-03-17Colony count [#/volume] in Urine100000{CFU}/mLIn a catheterized conduit specimen, 10,000 CFU/mL or more of one organism with symptoms supports infectionHighS
2026-06-02Patient Health Questionnaire 2 item (PHQ-2) total score [Reported]0{score}S
2026-06-02Total score [Mini-Cog]5{score}S
2026-06-02Total score [AUDIT-C]2{score}S
2026-06-02Cholesterol [Mass/volume] in Serum or Plasma196mg/dL<=200 mg/dLNormalS
2026-06-02Cholesterol in HDL [Mass/volume] in Serum or Plasma46mg/dL>=40 mg/dLNormalS
2026-06-02Cholesterol in LDL [Mass/volume] in Serum or Plasma by calculation124mg/dL<=129 mg/dLNormalS
2026-06-02Triglyceride [Mass/volume] in Serum or Plasma130mg/dL<=149 mg/dLNormalS

Social History

Vital Signs

DateMeasureValueUnitProvenance
2026-01-06Body height180cmS
2026-01-06Body weight76.5kgS
2026-01-06Body mass index (BMI) [Ratio]23.6kg/m2S
2026-01-06Systolic blood pressure126mm[Hg]S
2026-01-06Diastolic blood pressure76mm[Hg]S
2026-01-06Heart rate74/minS
2026-01-06Respiratory rate14/minS
2026-01-06Body temperature36.7CelS
2026-01-06Oxygen saturation in Arterial blood by Pulse oximetry97%S
2026-02-03Body height180cmS
2026-02-03Body weight77.2kgS
2026-02-03Body mass index (BMI) [Ratio]23.8kg/m2S
2026-02-03Systolic blood pressure128mm[Hg]S
2026-02-03Diastolic blood pressure78mm[Hg]S
2026-02-03Heart rate72/minS
2026-02-03Respiratory rate14/minS
2026-02-03Body temperature36.6CelS
2026-02-03Oxygen saturation in Arterial blood by Pulse oximetry97%S
2026-04-07Body height180cmS
2026-04-07Body weight77.6kgS
2026-04-07Body mass index (BMI) [Ratio]24kg/m2S
2026-04-07Systolic blood pressure126mm[Hg]S
2026-04-07Diastolic blood pressure74mm[Hg]S
2026-04-07Heart rate70/minS
2026-04-07Respiratory rate14/minS
2026-04-07Body temperature36.6CelS
2026-04-07Oxygen saturation in Arterial blood by Pulse oximetry98%S
2026-07-07Body height180cmS
2026-07-07Body weight78.8kgS
2026-07-07Body mass index (BMI) [Ratio]24.3kg/m2S
2026-07-07Systolic blood pressure128mm[Hg]S
2026-07-07Diastolic blood pressure76mm[Hg]S
2026-07-07Heart rate70/minS
2026-07-07Respiratory rate14/minS
2026-07-07Body temperature36.7CelS
2026-07-07Oxygen saturation in Arterial blood by Pulse oximetry97%S
2026-03-17Body height180cmS
2026-03-17Body weight76.9kgS
2026-03-17Body mass index (BMI) [Ratio]23.7kg/m2S
2026-03-17Systolic blood pressure118mm[Hg]S
2026-03-17Diastolic blood pressure70mm[Hg]S
2026-03-17Heart rate98/minS
2026-03-17Respiratory rate18/minS
2026-03-17Body temperature38.4CelS
2026-03-17Oxygen saturation in Arterial blood by Pulse oximetry96%S
2026-06-02Body height180cmS
2026-06-02Body weight78.4kgS
2026-06-02Body mass index (BMI) [Ratio]24.2kg/m2S
2026-06-02Systolic blood pressure128mm[Hg]S
2026-06-02Diastolic blood pressure76mm[Hg]S
2026-06-02Heart rate70/minS
2026-06-02Respiratory rate14/minS
2026-06-02Body temperature36.6CelS
2026-06-02Oxygen saturation in Arterial blood by Pulse oximetry97%S

Encounters

DatePurposeStatusProvenance
2026-01-06First visit to establish shared care three months after radical cystoprostatectomy with an ileal conduit for bladder cancerfinishedS
2026-02-03Four-week follow-up with urology consultation: surveillance plan, stoma and peristomal skin, and metabolic monitoringfinishedS
2026-04-07Six-month post-cystectomy follow-up: kidney function, acid-base, upper-tract ultrasound, and review after a kidney infectionfinishedS
2026-07-07Nine-month post-cystectomy follow-up: acid-base on bicarbonate, stoma review, and the surveillance schedulefinishedS
2026-03-17Same-day sick visit for fever and right flank painfinishedS
2026-06-02Subsequent annual wellness visitfinishedS

Plan of Treatment

InterventionStatusGuidelineProvenance
Urology consultation to share survivorship surveillance after radical cystectomy, review the stoma, and set the metabolic monitoring plancompletedGL-AUA-MIBC-2024, GL-NCCN-BLADDER-2026S
Cancer surveillance after cystectomy for pT2a N0 disease: CT or MRI of the chest, abdomen, and pelvis every 6 to 12 months for 2 to 3 years, then yearly; no adjuvant therapycompletedGL-AUA-MIBC-2024, GL-CMID-2026, GL-NCCN-BLADDER-2026S
Kidney and metabolic monitoring after an ileal conduit: chemistry with creatinine, chloride, and bicarbonate every 3 to 6 months in the first year, then yearly; upper-tract imaging every 6 months to year 3; vitamin B12 yearly; alkali for bicarbonate below 22 mmol/LcompletedGL-AUA-MIBC-2024, GL-CMID-2026S
Stoma care with the wound, ostomy, and continence nurse: appliance fitting, peristomal skin care, and parastomal hernia checkscompletedGL-AUA-MIBC-2024, GL-CMID-2026S
Urine infection plan with a conduit: no routine urine cultures or treatment of bacteriuria without symptoms; for fever, flank pain, or rigors, a culture taken by catheter from the stoma and prompt treatment; about 2 liters of fluid a daycompletedGL-AUA-MIBC-2024, GL-IDSA-CUTI-2025S
Distress screening at each visit, physical activity, and a written survivorship care plancompletedGL-CMID-2026, GL-NCCN-BLADDER-2026S

Goals

GoalTargetStatusOutcomeProvenance
Leak-free urostomy appliance with healthy peristomal skin2026-04-07completedAppliance refitted with a convex wafer at the consultation; no leaks in the two months after the refit and skin healedS
Stable kidney function (creatinine within 0.3 mg/dL of the post-operative baseline) and bicarbonate 22 mmol/L or more2026-07-07completedCreatinine 1.10 mg/dL; bicarbonate 24 mmol/L on sodium bicarbonateS
Regain stamina after surgery: walk 30 minutes a day and regain weight2026-04-07completedWalking 30 minutes most days; weight up 1.1 kg since the first visitS
Written survivorship surveillance schedule in place, shared between urology and primary care2026-07-07completedSchedule given; CT due at one year after surgeryS

Functional Status

Mental Status